Health TrialsbyHealthPanel

Effects of Calamansi on Blood Glucose and Insulin Levels

ConditionCalamansi Powder Capsule Supplementation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-30
SponsorBurapha University

About this trial

Fifty-four healthy sedentary male and female participants aged 18-30 years will be recruited for this study. Participants will be randomly assigned to one of two groups: a control group receiving placebo MMC capsules (n = 27) or a calamansi capsule supplementation group (n = 27). All participants will undergo health screening procedures, including medical history assessment, mental health questionnaire evaluation, and measurements of vital signs, height, body weight, and body composition. Venous blood samples will subsequently be collected to determine blood glucose, insulin, creatinine, alanine aminotransferase (ALT), and malondialdehyde (MDA) levels. These assessments will be performed at three time points: 1) before capsule supplementation (baseline), 2) following a single dose of capsule supplementation, and 3) after 12 weeks of supplementation.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Healthy individuals who have not been diagnosed with diabetes or prediabetes, with a fasting blood glucose level (after 8 hours of fasting) of less than 100 mg/dL.

Aged between 18-30 years, both male and female

Body Mass Index (BMI) between 18.5 and 22.9 kg/m²

No diseases affecting blood sugar levels, such as liver or pancreatic diseases

Disqualifiers

Pregnant or breastfeeding women

Regular smokers

Regular alcohol consumers

Individuals with a history of allergies to citrus fruits or citrus-derived ingredients

Trial design

Design model

Parallel

Treatments tested in this trial

  • MMC powder capsule

    Other intervention

    Each capsule contains MMC powder for 500 mg

  • Calamansi powder capsule

    Dietary supplement

    Each capsule contains calamansi powder for 500 mg

Treatment groups

54 Participants
are divided into 2 treatment groups
Group A: MMC powder capsulePlacebo comparator 1 intervention
Group B: Calamansi powder capsuleExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Concentrations of blood glucose

Concentrations of blood glucose were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in mg/dL unit

Time frame
At 0 minute before consumption, at 30, 60, 90, 120 minutes after consumption, and at days 91 after consumption
2

Concentrations of blood insulin

Concentrations of blood insulin were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uU/mL (microunit/milliliter) unit

Time frame
At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption
3

Concentrations of blood malondialdehyde

Concentrations of blood malondialdehyde were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uM (micromolar) unit

Time frame
At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption

Secondary outcomes

1

Levels of heart rate variability

Heart rate variability were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in ms (milliseconds) and ms2 (millisecond squared) unit

Time frame
At 0-10 minutes before consumption, at 110-120 minutes after consumption, and at days 91 after consumption for 10 minutes

Other outcomes

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

Piyapong PrasertsriRecruiting20131, Mueang, Burapha UniversityThailandThailand

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Burapha University

Lead sponsor

Source ClinicalTrials.gov
Apply now